Asia tech stocks slide tracking Wall St losses amid AI doubts, govt. uncertainty
JUPITER, Fla. - Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), currently trading near its 52-week high with a market capitalization of $3 billion, announced Thursday it has completed its offering of 0.75% convertible senior notes due 2030, raising $460 million in aggregate principal amount. According to InvestingPro data, the company maintains a strong financial position with more cash than debt on its balance sheet.
The offering included the full exercise of the initial purchasers’ option to buy an additional $60 million in notes. Net proceeds totaled approximately $445.1 million after deducting fees and expenses.
Ligand allocated approximately $45.9 million of the proceeds to pay for convertible note hedge transactions, which were partially offset by proceeds from warrant transactions. The company also used about $15 million to repurchase 102,034 shares of its common stock at $147.01 per share through privately negotiated transactions.
The biopharmaceutical company plans to use the remaining proceeds for general corporate purposes.
In connection with the offering, Ligand entered into convertible note hedge transactions with certain financial institutions to reduce potential dilution to its common stock upon note conversion. The company also entered into warrant transactions with strike prices initially set at $294.02 per share, representing a 100% premium over Ligand’s last reported share price at the time of pricing.
Ligand Pharmaceuticals focuses on enabling scientific advancement through financing and licensing technologies for clinical development of medicines. The company operates with a business model centered on creating a diversified portfolio of biotech and pharmaceutical product revenue streams.
This information is based on a press release statement from the company.
In other recent news, Ligand Pharmaceuticals has successfully priced $400 million in 0.75% convertible senior notes due in 2030, with a private placement to qualified institutional buyers. The company also provided an option for initial purchasers to acquire an additional $60 million in notes, with the offering expected to close on August 14. Ligand reported a strong financial performance for the second quarter of 2025, with revenue reaching $47.6 million, a 15% increase year-over-year, surpassing consensus estimates by approximately 9%. The company’s adjusted earnings per share (EPS) also exceeded expectations at $1.60 compared to the forecasted $1.43. RBC Capital raised its price target for Ligand to $185 from $155, maintaining an Outperform rating following these results. Similarly, Oppenheimer increased its price target to $167 from $162, highlighting strong royalty growth. Royalty revenue notably grew by 57% year-over-year, contributing significantly to the company’s overall performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.